摘要
临床抗高血压药物之间的联用较常见,其优势在于药物作用机制互补,较各单药疗效增加,血压可更快达标且药物不良反应发生率降低。全球第一个血管紧张素受体拮抗剂/钙离子拮抗剂的单片复方制剂缬沙坦/氨氯地平片已在中国上市,主要用于治疗原发性高血压,尤其单药治疗不能充分控制血压的患者。本文综述该药临床药理学研究进展,为临床合理用药提供参考。
The combined utilization of anti-hypertension drugs is common in clinical practice. It can enhance the single drug effect, promote blood pressure to be normal faster and decrease the adverse drug reactions by complementation actions. The very first monolithic compound preparation of angiotensin receptor blocker/calcium channel blocker in the world （Valsartan/Amlodipine） has already been introduced into China. It is mainly prescribed for primary hypertension, especially for those whose blood pressure can＇t be well controlled by a single drug. The research progress for the clinical pharmacology of this drug was reviewed in this article so as to provide reference for rational drug use in clinical treatment.
出处
《中国执业药师》
CAS
2011年第12期31-36,共6页
China Licensed Pharmacist
基金
安徽省教育厅优秀青年人才基金(2010SQRL175)
关键词
缬沙坦
氨氯地平
抗高血压药物
临床药理学
Valsartan
Amlodipine
Antihypertensive Agents
Clinical Pharmacology
